Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Çѱ¹Àο¡¼­ ¹ß»ýÇÑ ºñÈ£ÁöŲ ¸²ÇÁÁ¾¿¡¼­ Epstein-Barr Virus Nuclear AntigenÀÇ °ËÃâ¿¡ °üÇÑ ¿¬±¸ Sporadic Non-Hodgkin

´ëÇѾÏÇÐȸÁö 1997³â 29±Ç 3È£ p.473 ~ 485
À̹̼÷, È«¼øÇ¥, ÃÖºÀ³², ÇÏ»óÈ£,
¼Ò¼Ó »ó¼¼Á¤º¸
À̹̼÷ ( Lee Mi-Sook ) 
Á¶¼±´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç

È«¼øÇ¥ (  ) 
Á¶¼±´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
ÃÖºÀ³² ( Choi Bong-Nam ) 
Á¶¼±´ëÇб³ ÀÇ°ú´ëÇÐ À̺ñÀÎÈÄ°ú±³½Ç
ÇÏ»óÈ£ (  ) 
Á¶¼±´ëÇб³ ÀÇ°ú´ëÇÐ Á¤Çü¿Ü°úÇб³½Ç

Abstract

¼­·Ð
Epstein-Barr virus(EBV)´Â DNA gamma herpes ¹ÙÀÌ·¯½ºÀÇ ÀÏÁ¾À¸·Î B ¸²ÇÁ±¸¸¦ ¼±ÅÃ
ÀûÀ¸·Î ħ¹üÇÏ¿© ¼¼Æ÷ºÐ¿­À» ÀÚ±ØÇÏ¿© B ¸²ÇÁ±¸ÀÇ ºÒ¸êÈ­¸¦ ÃÊ·¡ÇÏ´Â ¸²ÇÁÃßÇ⼺ ¹ÙÀÌ·¯½º
ÀÌ´Ù. EBV´Â Àü¿°¼º ´ÜÇÙ±¸Áõ, ¾ÆÇÁ¸®Ä«Çü Burkitt ¸²ÇÁÁ¾°ú ¸é¿ª±â´ÉÀÌ ÀúÇÏµÈ È¯ÀÚ¿¡¼­
¹ß»ýÇÑ B ¼¼Æ÷ ¸²ÇÁÁ¾, ºñÀεξÏÁ¾°ú ¹ÐÁ¢ÇÑ °ü·Ã¼ºÀÌ ÀÖ´Ù°í ¾Ë·ÁÁ® ÀÖ´Ù. ƯÈ÷ À̵é Á¾¾ç
¼¼Æ÷¿¡¼­ EBVÀÇ Å¬·Ð¼º Áõ½ÄÀÌ °üÂûµÊÀ¸·Î¼­ EBV°¡ Á¾¾ç ¹ß»ý¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ´ã´çÇÏ°í
ÀÖÀ½ÀÌ Áõ¸íµÇ¾ú´Ù.
ÃÖ±Ù¿¡´Â È£ÁöŲº´°ú T ¼¼Æ÷ ºñÈ£ÁöŲ ¸²ÇÁÁ¾ÀÇ ¹ß»ý°úµµ °ü°è°¡ ±Ô¸íµÇ¾î Á¾¾ç¹ß»ý¿¡
°üÇÑ EBVÀÇ ¿ªÇÒ¿¡ ´ëÇؼ­ °ü½Éµµ°¡ Áõ°¡µÇ°í ÀÖ´Ù. ±×·¯³ª EBV°¡ ¾î¶°ÇÑ °æ·Î¸¦ °ÅÃÄ T
¼¼Æ÷¾Ç¼º ¸²ÇÁÁ¾ÀÇ Á¾¾ç¼¼Æ÷¿¡ ħÀÔÇÏ¿´´ÂÁö´Â Àß ¾Ë·ÁÁ® ÀÖÁö ¾ÊÁö¸¸, ÃÖ±Ù ¸»ÃÊÇ÷¾× T ¼¼
Æ÷¿¡¼­ EBV¿¡ ´ëÇÑ ¼ö¿ëü(CD2l)°¡ ¹ßÇöµÈ´Ù´Â ¿¬±¸ º¸°í°¡ ¹ßÇ¥µÈ ÈÄ ÀÌ¿¡ ´ëÇÑ ±âÀüÀÌ
Á¡Â÷ ¹àÇôÁö±â ½ÃÀÛÇÏ¿´´Ù. ±×¸®°í ¸é¿ª±â´ÉÀÇ °áÇÌÀ» ³ªÅ¸³»´Â »ç¶÷¿¡°Ô¼­ ¹ß»ýÇÏ´Â B¼¼Æ÷
¸²ÇÁÁ¾Àº EBV¿¡ °¨¿°µÈ B ¼¼Æ÷ÀÇ Áõ½ÄÀÌ Á¤»óÀûÀÎ Á¶Àý´É·ÂÀ» »ó½ÇÇϹǷνá B ¼¼Æ÷ ¸²ÇÁ
Á¾À¸·Î ¹ßÀüÇÏ´Â °ÍÀ¸·Î Àß ±Ô¸íµÇ¾î ÀÖ´Ù ±×·¯³ª Á¾Á¾ °íºÐÈ­ B ¼¼Æ÷ ¸²ÇÁÁ¾, nonendemic
Burkitt ¸²ÇÁÁ¾, ¿ø¹ß¼º ÁßÃ߽Ű渲ÇÁÁ¾ ¹× hairy-cell ¹éÇ÷º´È¯ÀÚ¿¡¼­ EBV°¡ µå¹°°Ô °ËÃâµÇ
¾úÀ¸³ª, ¸é¿ª¾ïÁ¦ »óÅ¿¡ ÀÖÁö ¾Ê´Â ȯÀÚ¿¡¼­ ¹ß»ýÇÏ´Â »ê¹ß¼º ºñÈ£ÁöŲ ¸²ÇÁÁ¾°ú EBV¿ÍÀÇ
°ü·Ã¼ºÀº ¾ÆÁ÷ Àß ¾Ë·ÁÁöÁö ¾Ê´Â ½ÇÁ¤ÀÌ´Ù. ¶ÇÇÑ ¿ì¸®³ª¶ó¿¡¼­ ¹ß»ýÇÑ ºñÈ£ÁöŲ ¸²ÇÁÁ¾¿¡
´ëÇÑ ÀÓ»óÀû ¼Ò°ß, º´¸®ÇÐÀû ¼Ò°ß ¹× EBVÀÇ °Ë»öµîÀº ±ØÈ÷ »ê¹ßÀûÀ¸·Î º¸°íµÇ¾î Æ÷°ýÀûÀÎ
Á¤º¸¸¦ ¾ò±â ¾î·Á¿î ½ÇÁ¤ÀÌ´Ù.
ÀÌ¿¡ ÀúÀÚ´Â Çѱ¹Àο¡¼­ »ê¹ßÀûÀ¸·Î ¹ß»ýÇÑ ºñÈ£ÁöŲ ¾Ç¼º ¸²ÇÁÁ¾À» ±¹Á¦ ÀÓ»óÀû°ø½Ä
(International Working Formulation)¿¡ µû¶ó ºÐ·ùÇÏ°í, ¸é¿ªÁ¶Á÷È­ÇÐÀû ¿°»öÀ» ÅëÇÏ¿© ¸é¿ª
Ç¥ÇöÇüÀ» °üÂûÇÏ°í, ÁßÇÕÈ¿¼Ò ¿¬¼â¹ÝÀÀ¹ý(polymerase chain reaction; PCR)À» ÅëÇÏ¿© EBV
°Ô³ð À¯¹«¸¦ °üÂûÇÏ¿© ºñÈ£ÁöŲ ¾Ç¼º ¸²ÇÁÁ¾ÀÇ ¸é¿ªÇ¥ÇöÇü¿¡ µû¸¥ EBV¿ÍÀÇ °ü·Ã¼ºÀ» ±Ô¸í
ÇÏ°íÀÚ º» ¿¬±¸¸¦ ½ÃÇàÇÏ¿´´Ù.
#ÃÊ·Ï#
Purpose : It's well known that the Epstein-Barr virus(EBV) is associated with
endemic Burkitt's lymphoma and B cell lymphomas in immunocompromised individuals,
and undifferentiated carcinoma of the nasopharynx. A clonotypic proliferation of EBV
has been demonstrated in the neoplastic cells of these malignancies, suggesting a
causative role of EBV in the tumorigenesis. More recently, it was identified that EBV
has been linked to Hodgkin's disease and B or T-cell non-Hodgkin's lymphomas(NHLs)
without preexisting immunodeficiency .
Material and Method : To determine the immunophenotype and incidence of EBV
infection in sporadic NHLs of Korea, We investigated 90 cases of NHLs through
immunchistochemistry and polymerase chain reaction, respectively.
Results : Sixty-nine of 90(77%) of NHLs are of B-cell type, 18 of 90(20%) of NHLs
are of T-cell type and 3 out of 90(3%) of NHLs are undefined lineage by
immunohistochemistry. EBV genome was detected in 7 out of 69(10%) B-cell
lymphomas, 5 out of 18(28%) f¡¤cell lymphomas and 1 out of 3(33%) non-B and non-T
cell lymphomas by polymerase chain reaction. The male/female ratio of EBV-positive
NHLs was 2.25: 1. There are no prominent differences in age distribution and tumor
localization between EBV-positive groups and negative groups.
Conclusion : EBV positivity in T-cell NHLs is rather higher than in B-cell NHLs and
this finding suggests that there is inter-relation association between EBV and T-cell
NHLs, although the exact nature of this association remains to be established.

Å°¿öµå

EBV; Non-Hodgkin's lymphoma; Immunohistochemistry; PCR;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS